Avonex®
Sponsors
EMD Serono, Teva Branded Pharmaceutical Products R&D, Inc., Biocad, EMD Serono Research & Development Institute, Inc.
Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingRelapsing Remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis
Phase 2
Phase 3
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
CompletedNCT00292266
Start: 1999-11-30End: 2002-06-30Updated: 2013-08-05
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
CompletedNCT00605215
Start: 2008-04-24End: 2011-06-10Updated: 2022-04-21
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
WithdrawnNCT01975298
Start: 2014-01-31End: 2014-03-31Updated: 2021-11-09
Study of Evobrutinib in Participants With RMS
TerminatedNCT04032171
Start: 2019-09-10End: 2020-05-20Updated: 2021-08-05
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
TerminatedNCT04032158
Start: 2019-08-26End: 2020-04-16Updated: 2021-08-05